[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608511":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":45,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Snoezelen","EXPERIMENTAL","Participants will be enrolled between their first chemotherapy cycle (without Snoezelen) and their second cycle (with Snoezelen). During the study, they will complete self-report questionnaires assessing anxiety, depression, quality of life, and nausea. They will receive 45-minute Snoezelen sessions every two days during their second hospitalization. After the final session, participants will take part in a semi-structured interview. In addition, data will be collected on medications administered (anxiolytics and antiemetics) and on the frequency of vomiting during both hospital stays.",[13],"Other: self-report questionnaires, research interviews",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"self-report questionnaires, research interviews","self-report questionnaires and research interviews",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Fanny BEN OUNE","CONTACT","+33320295918","promotion@o-lambret.fr",[27],{"facility":5,"status":28,"city":29,"state":19,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Lille","59000","France","FR",{"type":34,"coordinates":35},"Point",[36,37],3.05512,50.63391,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":42,"phoneExt":19,"email":25},"Sylvie MERCIER","+33 03 20 29 59 59",{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[46,49],{"name":47,"class":48},"PETRARQUE","UNKNOWN",{"name":50,"class":6},"Scalab CNRS 9193","100608511","proof-of-concept-study-of-the-snoezelen-device-on-anxiety-symptoms-in-patients-hospitalized-for-chemotherapy-in-a-pediatric-oncology-department-100608511",false,"NCT07202507","Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department","SNOOZE","Inclusion Criteria:\n\n* New patient\n* Treated in the Paediatrics\u002FAJA department of the Oscar Lambret Centre for cancer (all types of cancer)\n* Hospitalisation for several days\n* Highly emetogenic chemotherapy treatment: this corresponds to all in-patient treatments carried out in the Paediatrics\u002FAJA department.\n* Age at diagnosis : ≥ 8 years and \\\u003C 18 years.\n* French language\n* Information for the patient and those with parental authority; consent signed by the patient and those with parental authority.\n* Valid social security cover\n\nExclusion Criteria:\n\n* Contraindication to SNOEZELEN:\n\n  * Claustrophobia\n  * Presence of psychiatric, addictive or cognitive disorders that would prevent compliance with the protocol requirements;\n* State of health not allowing participation in the study (severe fatigue, symptoms refractory to treatment).\n* Pregnant or breast-feeding women","ALL","8 Years","18 Years",{"count":62,"type":63},20,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit.\n\nResearchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being.\n\nParticipants will:\n\n* Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles\n* Complete self-report questionnaires on anxiety, depression, quality of life, and nausea\n* Receive 45-minute Snoezelen sessions every two days during their second hospitalization\n* Participate in a semi-structured interview after the final session\n* Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations",[9,69,70,71],"Pediatric Cancer","Symptomatologie Anxieuse","Chimiothérapie",[9,69],"2026-03-16",{"date":75,"type":76},"2026-03-18","ACTUAL",{"date":78,"type":63},"2027-09",{"date":80,"type":63},"2027-10-31",{"name":5,"class":6},1]